Journal
HUMAN MOLECULAR GENETICS
Volume 22, Issue 1, Pages 74-83Publisher
OXFORD UNIV PRESS
DOI: 10.1093/hmg/dds403
Keywords
-
Funding
- Kidney Research UK [RP42/2009]
- Cancer Research UK [C20791/A12743]
- Dorothy Hodgkin postgraduate fellowship
- BBSRC [BB/F022298/1, BB/J016489/1] Funding Source: UKRI
- NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM098609] Funding Source: NIH RePORTER
- Biotechnology and Biological Sciences Research Council [BB/J016489/1, BB/F022298/1] Funding Source: researchfish
- Cancer Research UK [12743] Funding Source: researchfish
Ask authors/readers for more resources
Although tumour suppressor gene hypermethylation is a universal feature of cancer cells, little is known about the necessary molecular triggers. Here, we show that Wilms tumour 1 (WT1), a developmental master regulator that can also act as a tumour suppressor or oncoprotein, transcriptionally regulates the de novo DNA methyltransferase 3A (DNMT3A) and that cellular WT1 levels can influence DNA methylation of gene promoters genome-wide. Specifically, we demonstrate that depletion of WT1 by short-interfering RNAs leads to reduced DNMT3A in Wilms tumour cells and human embryonal kidney-derived cell lines. Chromatin immunoprecipitation assays demonstrate WT1 recruitment to the DNMT3A promoter region and reporter assays confirm that WT1 directly transactivates DNMT3A expression. Consistent with this regulatory role, immunohistochemical analysis shows co-expression of WT1 and DNMT3A proteins in nuclei of blastemal cells in human fetal kidney and Wilms tumours. Using genome-wide promoter methylation arrays, we show that human embryonal kidney cells over-expressing WT1 acquire DNA methylation changes at specific gene promoters where DNMT3A recruitment is increased, with hypermethylation being associated with silencing of gene expression. Elevated DNMT3A is also demonstrated at hypermethylated genes in Wilms' tumour cells, including a region of long-range epigenetic silencing. Finally, we show that depletion of WT1 in Wilms tumour cells can lead to reactivation of gene expression from methylated promoters, such as TGFB2, a key modulator of epithelialmesenchymal transitions. Collectively, our work defines a new regulatory modality for WT1 involving elicitation of epigenetic alterations which is most likely crucial to its functions in development and disease.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available